A champion of women in leadership, Drexler brings wealth of
experience at both commercial-stage and start-up medtech and
healthcare companies
Also at annual meeting of shareholders, long-serving Director
Chris Roberts announced his
retirement
SAN DIEGO, Nov. 17, 2017 /CNW/ -- ResMed (NYSE: RMD, ASX:
RMD) today announced it has elected accomplished healthcare
executive Karen Drexler to its Board
of Directors.
Experience the interactive Multichannel News Release here:
https://www.multivu.com/players/English/7462953-resmed-board-of-directors-karen-drexler/
Additionally, Dr. Chris Roberts
is retiring after serving on ResMed's Board for more than 25 years.
Ms. Drexler's appointment and Dr. Roberts' retirement both took
effect following the company's annual meeting of shareholders held
Thursday afternoon.
Ms. Drexler has been a board member for public and private
digital health, medical device, and diagnostic companies for more
than a decade, and has extensive management experience as both a
founder and CEO. She currently serves as CEO and board member of
Sandstone Diagnostics, a commercial-stage consumer diagnostics
company.
"I'm thrilled to welcome Karen
Drexler to ResMed's Board," said ResMed Founder and Board
Chairman Peter Farrell. "Her deep
expertise in advising and managing medical device, digital health
and diagnostic companies, and particularly her experience in
technology and out-of-hospital care models, will serve ResMed well
as we continue to deepen our leadership in connected care and
digital health."
"I'd also like to thank Chris
Roberts for his long and meaningful service to ResMed
spanning more than a quarter-century," said Farrell.
Ms. Drexler is an active mentor and advisor with Astia, a global
nonprofit focused on female founders, and is a founding member of
Astia Angels, a network of investors who fund such founders. Ms.
Drexler was also president and CEO of Amira Medical Inc., developer
of minimally invasive glucose monitoring technologies, from 1996
until it was sold to Roche Holding AG in 2001. From 1984 to 1995,
she held various positions at LifeScan and played a key role in the
company's sale to Johnson & Johnson in 1986.
Dr. Roberts served as a member of ResMed's board from 1989 to
1990, and from 1992 until his retirement. Dr. Roberts is a longtime
medtech innovator. From 2004 to 2015, he served as CEO, president
and board member of Cochlear Limited, a leader in the treatment of
severe and profound hearing impairment.
About ResMed
ResMed (NYSE: RMD, ASX: RMD) changes
lives with award-winning medical devices and cloud-based software
applications that better diagnose, treat and manage sleep apnea,
chronic obstructive pulmonary disease (COPD) and other chronic
diseases. ResMed is a global leader in connected care, with more
than 4 million patients remotely monitored every day. Our
6,000-strong team is committed to creating the world's best
tech-driven medical device company – improving quality of life,
reducing the impact of chronic disease, and saving healthcare costs
in more than 120 countries. ResMed.com | Facebook | Twitter |
LinkedIn
For
media:
|
For
investors:
|
Alison
Graves
|
Agnes Lee
|
+1
858-836-6789
|
+1
858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|
Logo -
https://mma.prnewswire.com/media/588826/RESMED_INC__LOGO.jpg
View original
content:http://www.prnewswire.com/news-releases/resmed-elects-karen-drexler-to-its-board-of-directors-300558439.html
SOURCE ResMed, Inc.